GlassScriptPhysician profile
Craig M Patterson
NPI 1063624377
$4,112.10
in general payments reported to CMS, 2019-2025
34 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 77% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $418 · 2021: $618 · 2022: $295 · 2023: $385 · 2024: $453 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $870.78 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Actelion Pharmaceuticals US, INC. | $663.74 | 2019-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $378.39 | 2019-2025 | Fasenra, Tagrisso, Tezspire |
| Glaxosmithkline, LLC. | $286.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Bayer Healthcare Pharmaceuticals INC. | $258.57 | 2019-2025 | |
| Insmed, INC. | $206.83 | 2023-2025 | Arikayce |
| Vantive US Healthcare LLC | $174.16 | 2025 | Renal - Acute, Renal - Prismalung |
| Merck Sharp & Dohme LLC | $169.65 | 2024-2025 | Winrevair |
| Janssen Pharmaceuticals, INC | $162.35 | 2019-2021 | |
| Pfizer INC. | $144.91 | 2019-2024 | |
| Boston Scientific Corporation | $88.04 | 2024 | Ekosonic |
| Mallinckrodt Enterprises LLC | $68.25 | 2019 | |
| Amgen INC. | $66.95 | 2024-2025 | Tezspire |
| Mylan Specialty L.P. | $65.05 | 2019-2024 | Yupelri |
| Viatris Specialty LLC | $42.45 | 2025 | Yupelri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $41.49 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $40.38 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.24 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $34.95 | 2019-2022 | |
| Edwards Lifesciences Corporation | $34.69 | 2024 | Hemosphere |
| Zoll Medical Corporation | $33.07 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.65 | 2019-2021 | |
| Sandoz INC. | $28.37 | 2023 | Treprostinil |
| Genzyme Corporation | $24.57 | 2025 | |
| Advanced Respiratory, INC | $22.79 | 2019 | |
| Verona Pharma, INC. | $22.14 | 2025 | Ohtuvayre |
| Philips North America LLC | $20.76 | 2025 | Vest Therapy Und |
| Olympus America INC. | $16.67 | 2021 | |
| Grifols USA, LLC | $16.23 | 2025 | Prolastin-C Liquid |
| Abbott Laboratories | $14.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.78 | 2022 | |
| Resmed Corp | $13.31 | 2022 | |
| Pulmonx Corporation | $12.94 | 2020 | |
| Inogen, INC. | $2.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.